Menu Search
Equities

ARCA Biopharma Inc

HQ10:FRA

ARCA Biopharma Inc

Actions
  • Price (EUR)3.20
  • Today's Change-0.14 / -4.19%
  • Shares traded1.03k
  • 1 Year change+82.34%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

  • Revenue in USD (TTM)0.00
  • Net income in USD-5.34m
  • Incorporated2004
  • Employees4.00
  • Location
    ARCA Biopharma Inc10170 Church Ranch Way, Suite 100WESTMINSTER 80021United StatesUSA
  • Phone+1 (720) 940-2200
  • Fax+1 (302) 655-5049
  • Websitehttps://arcabio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ABIO:NAQ since
announced		Transaction
value
Oruka Therapeutics IncAnnounced03 Apr 202403 Apr 2024Announced109.36%--
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.